A Phase I/IIa, Open-label, Randomised, Controlled, Multi-country, Dose-escalation Study to Assess the Safety and Immunogenicity of AS37 in Combination With the Hepatitis B Surface Antigen (HBsAg), According to a 0-1 Month Schedule, in Healthy, HBs naïve, Adults Aged 18-45 Years
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary) ; Aluminium hydroxide
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Acronyms EARLY-CLINRES-017
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
Most Recent Events
- 02 Jul 2024 Planned End Date changed from 2 Jan 2025 to 26 Dec 2024.
- 02 Jul 2024 Planned primary completion date changed from 6 Mar 2024 to 26 Dec 2024.
- 02 Jul 2024 Status changed from recruiting to active, no longer recruiting.